Primary Site >> Colorectal Cancer
Gene >> PGF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. PMID: 10463618 |
Ref: Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. PMID: 12702555 |
Ref: (64)Cu-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-quantum dot-vascular endothelial growth factor PMID: 20641777 |
Ref: Placenta growth factor expression is correlated with survival of patients with colorectal cancer. PMID: 15831913 |
Ref: Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. PMID: 16114015 Ref: Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells. PMID: 16440418 Ref: New marker of colon cancer risk associated with heme intake: 1,4-dihydroxynonane mercapturic acid. PMID: 17119057 |
Ref: Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in ApcMin/+ mice. PMID: 17283118 Ref: Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. PMID: 17437271 Ref: Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. PMID: 17704140 |
Ref: Cytotoxicity of Paclitaxel in biodegradable self-assembled core-shell poly(lactide-co-glycolide ethylene oxide fumarate) nanoparticles. PMID: 18196205 |
Ref: Acetylsalicylic acid regulates MMP-2 activity and inhibits colorectal invasion of murine B16F0 melanoma cells in C57BL/6J mice: effects of prostaglandin F(2)alpha. PMID: 18849138 Ref: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. PMID: 19470921 Ref: Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. PMID: 19647091 Ref: PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. PMID: 19657001 Ref: Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. PMID: 19826039 Ref: Cyclic AMP-mediated chloride secretion is induced by prostaglandin F2alpha in human isolated colon. PMID: 19889058 |
Ref: Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. PMID: 20484123 |
Ref: Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection. PMID: 21184108 Ref: sFLT01: a novel fusion protein with antiangiogenic activity. PMID: 21252283 Ref: Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer. PMID: 21337637 Ref: Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. PMID: 21407219 Ref: The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors. PMID: 21471210 |
Ref: Is serum placental growth factor a prognostic marker for stage III colorectal cancer patients? PMID: 22155858 Ref: The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells. PMID: 22170686 Ref: Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. PMID: 22363134 Ref: Exercise training reduces inflammatory mediators in the intestinal tract of healthy older adult mice. PMID: 22647663 Ref: Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PMID: 22701615 Ref: Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members. PMID: 23148666 Ref: Expression of placenta growth factor in colorectal carcinomas. PMID: 23346511 |
Ref: Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. PMID: 23562587 Ref: Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells. PMID: 23651517 Ref: Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. PMID: 23730520 Ref: Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. PMID: 23799978 |
Ref: Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. PMID: 24688047 Ref: Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. PMID: 24809949 Ref: Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. PMID: 25136356 Ref: Upregulation of stromal cell-derived factor 1alpha expression is associated with the resistance to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: angiogenic markers of neoadjuvant chemoradiation. PMID: 25241658 |
Ref: Chronic exposure of VEGF inhibitors promotes the malignant phenotype of colorectal cancer cells. PMID: 25817288 Ref: Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis. PMID: 25880726 Ref: Efficient inhibition of growth of metastatic cancer cells after resection of primary colorectal cancer by soluble Flt-1. PMID: 25895458 |
Ref: Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells. PMID: 27103202 Ref: Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). PMID: 27412031 Ref: Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. PMID: 27780936 |
Ref: An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. PMID: 28314990 Ref: Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. PMID: 28391576 |
Ref: Analyzing the molecular mechanism of the tissue specificity of gastrointestinal stromal tumors by using bioinformatics approaches. PMID: 30358224 |